What is ResMed's cash & equivalents?

ResMed (RMD) reported cash & equivalents of $1.66B in Q1 2026.

How has ResMed's cash & equivalents changed year-over-year?

ResMed's cash & equivalents increased by 78.0% year-over-year, from $932.71M to $1.66B.

What is the long-term trend for ResMed's cash & equivalents?

Over 4 years (2021 to 2025), ResMed's cash & equivalents has grown at a 42.3% compound annual growth rate (CAGR), from $295.28M to $1.21B.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

ResMed RMD Cash & Equivalents

Cash & Equivalents at other companies

Eli LillyLLY

$5.28B+70.8%

Five Point Holdings, Inc.FPH

$333.56M-37.0%

Inspire Medical SystemsINSP

$98.93M+83.6%

Viemed Healthcare, Inc.VMD

$9.76M-3.9%

LivaNovaLIVN

$539.71M-26.9%

AdaptHealthAHCO

$47.96M-10.6%

Other financials

Income statement

See full

Revenue$1.4B+10.8%

Gross profit$891.0M+16.3%

Operating income$499.8M+17.3%

Net income$398.7M+9.2%

EPS (diluted)$2.74+10.5%

Balance sheet

See full

Total debt$1.1B+29.8%

Total equity$6.5B+17.1%

Total assets$8.8B+16.1%

Cash flow

See full

Operating cash flow$554.1M-4.2%

CapEx$33.7M+61.8%

Free cash flow$520.5M-6.7%

Valuation

See full

Market cap$29.05B-22.6%

Enterprise value$28.5B-23.3%

P/E19.1×-7.7×

P/S5.3×-2.0×

Profitability

See full

Gross margin61.6%+2.8pp

Operating margin34.2%+2.1pp

Net margin27.4%+1.3pp

FCF margin31.7%+0.4pp

Returns & leverage

See full

Return on equity25.2%-0.6pp

Debt / equity0.2×0.0×

Current ratio3×-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ResMed's cash & equivalents?: ResMed (RMD) reported cash & equivalents of $1.66B in Q1 2026.
How has ResMed's cash & equivalents changed year-over-year?: ResMed's cash & equivalents increased by 78.0% year-over-year, from $932.71M to $1.66B.
What is the long-term trend for ResMed's cash & equivalents?: Over 4 years (2021 to 2025), ResMed's cash & equivalents has grown at a 42.3% compound annual growth rate (CAGR), from $295.28M to $1.21B.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.